We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need. Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now (link to ClinicalTrials.gov). We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq (NASDAQ: ANCN). Our R&D activities build upon the discovery by Professor Avraham Hochberg, of the Hebrew University of Jerusalem, of the human H19 gene. It has been shown that the gene is expressed in over forty different forms of cancer, including especially bladder cancer, while being quiescent in most normal adult tissues. H19-based therapy is designed to be a highly selective method of killing cancer cells that spares normal bladder tissue. Source
No articles found.
Aspyron Inc is development stage company that will be completing preparations for ...
Aspyron Inc is development stage company that w...
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the ...
Motus GI Holdings, Inc. is a medical technology...
Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering n...
Revance Therapeutics is a Silicon Valley-based ...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Acceleron is dedicated to the discovery and development of innovative, life-changi...
Acceleron is dedicated to the discovery and dev...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
Join the National Investor Network and get the latest information with your interests in mind.